BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30335046)

  • 1. OTC brimonidine (Lumify) for ocular redness.
    Med Lett Drugs Ther; 2018 Oct; 60(1558):176. PubMed ID: 30335046
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness.
    Torkildsen GL; Sanfilippo CM; DeCory HH; Gomes PJ
    Curr Eye Res; 2018 Jan; 43(1):43-51. PubMed ID: 29120262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial.
    McLaurin E; Cavet ME; Gomes PJ; Ciolino JB
    Optom Vis Sci; 2018 Mar; 95(3):264-271. PubMed ID: 29461408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials.
    Ackerman SL; Torkildsen GL; McLaurin E; Vittitow JL
    Clin Exp Optom; 2019 Mar; 102(2):131-139. PubMed ID: 30525235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilateral granulomatous uveitis in an elderly female.
    Kattige J; Konana VK; Babu K
    Indian J Ophthalmol; 2019 Sep; 67(9):1391. PubMed ID: 31436179
    [No Abstract]   [Full Text] [Related]  

  • 6. [Brimonidine (Mirvaso), dermal use].
    Van Genechten D
    J Pharm Belg; 2015 Jun; (2):45-6. PubMed ID: 26466509
    [No Abstract]   [Full Text] [Related]  

  • 7. Allergic contact dermatitis to topical brimonidine.
    Rajagopalan A; Rajagopalan B
    Australas J Dermatol; 2015 Aug; 56(3):235. PubMed ID: 26201375
    [No Abstract]   [Full Text] [Related]  

  • 8. The Results of Preoperative Use of Topical Brimonidine in Strabismus Surgery.
    Ucar F; Cetinkaya S
    J Ocul Pharmacol Ther; 2021 May; 37(4):230-235. PubMed ID: 33684337
    [No Abstract]   [Full Text] [Related]  

  • 9. A case of bilateral deep stromal corneal opacity and vascularization after use of multiple antiglaucoma medications including brimonidine tartrate ophthalmic solution.
    Tsujinaka A; Takai Y; Inoue Y; Tanito M
    Acta Ophthalmol; 2019 Sep; 97(6):e948-e949. PubMed ID: 30609169
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of timolol, benzalkonium-preserved timolol, and benzalkonium-preserved brimonidine on oxidative stress biomarkers in the tear film.
    Sedlak L; Wojnar W; Zych M; Wyględowska-Promieńska D
    Cutan Ocul Toxicol; 2020 Sep; 39(3):260-268. PubMed ID: 32594785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy.
    Lee JS; Kim CY
    Expert Rev Clin Pharmacol; 2022 Aug; 15(8):911-919. PubMed ID: 35951740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Brimonidine-induced interstitial keratitis: Case report].
    Szwarcberg L; Gabrielle PH; Guillarme-Sallit R; Creuzot-Garcher C; Arnould L
    J Fr Ophtalmol; 2024 Jun; 47(6):104122. PubMed ID: 38479333
    [No Abstract]   [Full Text] [Related]  

  • 13. Sedative and physiological effects of brimonidine tartrate ophthalmic solution in healthy cats.
    Ogata N; Kanda T; Kawahata M; Ichikawa T; Matsumoto Y; Morimitsu W; Nishino Y; Itoi T; Furumoto K
    Vet Anaesth Analg; 2017 Sep; 44(5):1091-1100. PubMed ID: 28865952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans.
    Takamura Y; Tomomatsu T; Matsumura T; Takihara Y; Kozai S; Arimura S; Yokota S; Inatani M
    J Ocul Pharmacol Ther; 2015 Jun; 31(5):282-5. PubMed ID: 25918904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of neuropsychiatric adverse events from topical ophthalmic brimonidine.
    Cimolai N
    Hum Exp Toxicol; 2020 Oct; 39(10):1279-1290. PubMed ID: 32347114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of ulcerated infantile hemangioma with brimonidine-timolol cream: 2 cases report and review of the literature.
    Almebayadh M
    J Dermatolog Treat; 2020 Jun; 31(4):433-434. PubMed ID: 30973791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients.
    Barwal I; Kumar R; Dada T; Yadav SC
    Microsc Microanal; 2019 Dec; 25(6):1352-1366. PubMed ID: 31018876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertensive acute granulomatous anterior uveitis as a side effect of topical brimonidine.
    Clemente-Tomás R; Arciniegas-Perasso CA; Hervás-Hernandis JM; García-Ibor F; Ruiz-Del Río N; Duch-Samper AM
    Arch Soc Esp Oftalmol (Engl Ed); 2018 Oct; 93(10):511-514. PubMed ID: 29910082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma.
    Gill K; Bayart C; Desai R; Golden A; Raimer P; Tamburro J
    Pediatr Dermatol; 2016 Jul; 33(4):e232-4. PubMed ID: 27282306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug.
    Park CG; Kim YK; Kim MJ; Park M; Kim MH; Lee SH; Choi SY; Lee WS; Chung YJ; Jung YE; Park KH; Choy YB
    J Control Release; 2015 Dec; 220(Pt A):180-188. PubMed ID: 26478018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.